Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 15/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1772830 | 0.83 | KIT (0.39) | KITNTRK1PIK3CAMAP3K11 | |
| SCHEMBL24565966 | 0.81 | KIT (0.48) | KITMAP3K11DYRK1A | |
| SCHEMBL25303525 | 0.79 | DYRK1A (0.50) | KITPIK3CAMAP3K11DYRK1A | |
| SCHEMBL10269012 | 0.77 | MET (0.43) | KITNTRK1PIK3CAMAP3K11DYRK1A | |
| SCHEMBL1093196 | 0.75 | RPS6KA5 (0.42) | KITNTRK1PIK3CAMAP3K11DYRK1A | |
| SCHEMBL10029796 | 0.73 | PIK3CA (0.47) | NTRK1PIK3CADYRK1ALRRK2 | |
| SCHEMBL25971496 | 0.73 | BRD4 (0.47) | KITNTRK1PIK3CAMAP3K11DYRK1A | |
| SCHEMBL24005850 | 0.73 | PRMT5 (0.42) | KITNTRK1MAP3K11DYRK1A | |
| SCHEMBL1774189 | 0.72 | NTRK1 (0.38) | KITNTRK1PIK3CAMAP3K11DYRK1A | |
| SCHEMBL1772956 | 0.72 | MAP3K11 (0.39) | KITNTRK1PIK3CAMAP3K11DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2265608-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | claimed |
| WO-2009111278-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | claimed |
| US-8338452-B2 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20110110889-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Bio Pharma Inc. (US) | 2011-05-12 | — | — | US | disclosed |
| EP-2265608-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009111278-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110110889-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | KIT 977/4885NTRK1 633/4885PIK3CA 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.